Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Participant with an out-of-range Screening laboratory values defined as shown below. NOTE: Hematology evaluations must be performed ≥ 7 days from any blood or blood product transfusion and ≥ 14 days from any dose of hematologic growth factor. Creatinine clearance < 30 mL/minute. Total bilirubin > 1.5 × ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin > 1.5 × ULN. Alanine aminotransferase > 5 × ULN in the presence of liver metastases; > 3 X ULN if not. Aspartate aminotransferase > 5 × ULN in the presence of liver metastases ; > 3 X ULN if not. Platelet count < 75 × 10^9/L. Hemoglobin < 9 g/dL. Clinically significant cardiac disease or impaired cardiac function, including any of the following: Congestive heart failure (New York Heart Association Class ≥ 3); QTcF>470msec at baseline; Uncontrolled hypertension defined as systolic blood pressure [BP] > 160 mmHg or diastolic BP > 110 mmHg; Acute myocardial infarction or unstable angina pectoris < 6 months prior to the planned first dose of program intervention.